Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (331-340 of 760) with videos related to

Pageof 76
Sort By:
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 10, 2006
"Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study"Pavel Cervinka, Marco A Costa, Dominick J Angiolillo, et al.
British Journal of Clinical Pharmacology|November 11, 2018
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patientsMagnus Åstrand, Carl Amilon, Daniel Röshammar, et al.
Journal of the American College of Cardiology|April 8, 2017
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac SurgerySubhash Banerjee, Dominick J Angiolillo, William E Boden, et al.
Journal of the American College of Cardiology|December 17, 2013
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2)Dominick J Angiolillo, Nicholas Curzen, Paul Gurbel, et al.
The Journal of Invasive Cardiology|August 5, 2005
Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registryMarco Costa, Dominick J Angiolillo, Paul Teirstein, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 14, 2025
Sex-Related Variations in Platelet Reactivity in Presence or Absence of Antiplatelet TherapyMattia Galli, Sergio Terracina, Eleonora Schiera, et al.
European Heart Journal|March 25, 2021
Antithrombotic therapy in diabetes: which, when, and for how long?Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 21, 2012
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus statusPiera Capranzano, Jose Luis Ferreiro, Masafumi Ueno, et al.
American Heart Journal|April 18, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysisAakash Garg, Amit Rout, Serdar Farhan, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 29, 2004
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantationDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
Pageof 76

Showing results (331-340 of 760) with videos related to

Sort By:
Pageof 76
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 10, 2006
"Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study"Pavel Cervinka, Marco A Costa, Dominick J Angiolillo, et al.
British Journal of Clinical Pharmacology|November 11, 2018
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patientsMagnus Åstrand, Carl Amilon, Daniel Röshammar, et al.
Journal of the American College of Cardiology|April 8, 2017
Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac SurgerySubhash Banerjee, Dominick J Angiolillo, William E Boden, et al.
Journal of the American College of Cardiology|December 17, 2013
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2)Dominick J Angiolillo, Nicholas Curzen, Paul Gurbel, et al.
The Journal of Invasive Cardiology|August 5, 2005
Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registryMarco Costa, Dominick J Angiolillo, Paul Teirstein, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 14, 2025
Sex-Related Variations in Platelet Reactivity in Presence or Absence of Antiplatelet TherapyMattia Galli, Sergio Terracina, Eleonora Schiera, et al.
European Heart Journal|March 25, 2021
Antithrombotic therapy in diabetes: which, when, and for how long?Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 21, 2012
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus statusPiera Capranzano, Jose Luis Ferreiro, Masafumi Ueno, et al.
American Heart Journal|April 18, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysisAakash Garg, Amit Rout, Serdar Farhan, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 29, 2004
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantationDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.
Pageof 76